ently GeoPharma employs nearly 300 people and operates facilities
in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas
utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and
laboratory facilities.
For further information visit the "For Investors" section of the
GeoPharma website at http://www.geopharmainc.com.
This press release may contain statements, which constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including those regarding the company and
its subsidiaries' expectations, intentions, strategies and beliefs
pertaining to future performance. All statements contained herein are based
upon information available to the company's management as of the date
hereof, and actual results may vary based upon future events, both within
and without management's control. Important factors that could cause such
differences are described in the company's periodic filings with the
Securities and Exchange Commission.
'/>"/>SOURCE GeoPharma, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen2.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients3.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 264.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering5.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.6.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets7.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results8.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain9.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter10.
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer11.
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line